Supernus Pharmaceuticals
SUPN
258 hedge funds and large institutions have $2.01B invested in Supernus Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 88 increasing their positions, 98 reducing their positions, and 29 closing their positions.
3,108% more call options, than puts
Call options by funds: $2.92M | Put options by funds: $91K
5% more capital invested
Capital invested by funds: $1.91B → $2.01B (+$99.5M)
0.79% less ownership
Funds ownership: 103.23% → 102.44% (-0.79%)
3% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 29
2% less funds holding
Funds holding: 263 → 258 (-5)
10% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 98
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$14.9M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$14.2M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$14.2M |
| 4 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$11.1M |
| 5 |
Renaissance Technologies
New York
|
+$5.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16.3M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$13.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11.1M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$9.89M |
| 5 |
LCG
Lisanti Capital Growth
New York
|
-$8.59M |
SUPN Hedge Fund Activity: Q1 2023 in Review
258 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2023, worth a combined $2.01B — up 5.2% from $1.91B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SUPN and 28 opened new positions — a net loss of 1 holder — while 98 trimmed existing stakes and 88 added.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $14.9M. The largest seller was Millennium Management, cutting an estimated $16.3M.
- 258 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2023, down from 263 in Q4 2022.
- Funds reported $2.01B of Supernus Pharmaceuticals stock for Q1 2023, up 5.2% quarter-over-quarter.
- 28 funds opened new Supernus Pharmaceuticals positions in Q1 2023 and 29 closed out, a net change of -1 holder.
- The largest Supernus Pharmaceuticals buyer in Q1 2023 was Pictet Asset Management (Switzerland), an estimated $14.9M added.
- The largest Supernus Pharmaceuticals seller in Q1 2023 was Millennium Management, an estimated $16.3M sold.
Based on aggregated 13F filings for Q1 2023.